- The FDA approved STAAR Surgical Company's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction.
- The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause dry eye syndrome, and, if required, can be removed by a doctor.
- EVO offers a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for distance vision correction.
- A U.S. multicenter, prospective clinical investigation confirmed the safety of the EVO family of myopia lenses.
- Read Next: BTIG Upgraded Staar Surgical Stock - Read Why.
- More than 100 clinical papers are available discussing the safety and efficacy of the Visian ICL family of lenses globally.
- Price Action: STAA shares are up 9.47% at $79.86 on the last check Monday.
